Leading brands under threat

Ophthalmology encompasses some lucrative markets, but the future of leading brands in AMD is under threat, and while established markets like glaucoma and conjunctivitis have many therapeutic options, diabetic retinopathy remains largely untapped. Key opinion leaders agree there is unmet need in terms of drug delivery methods and dose frequency across ophthalmology diseases.

Highlights

The future of leading brands Lucentis (ranibizumab) and Xalatan (latanoprost) is at risk. Lucentis dominates AMD with 91% market share but the use of currently off-label Avastin (bevacizumab, Roche) is a threat. Xalatan, the gold standard in glaucoma achieved $1.5 billion in 2008 but the drug faces generic erosion after patent expiry in 2011

Diabetic retinopathy and AMD markets show high growth potential. Both diseases are highly prevalent, with 11.5 million cases of diabetic retinopathy, and 7.5 million in AMD, in the seven major markets in 2010. There are few drug treatments for AMD, while no approved drugs for diabetic retinopathy mean this market is untapped.

Key opinion leaders report high unmet need for reduced dosing regimens of existing therapies and an improvement in drug delivery methods. However, any new formulations of existing drugs will have to compete with cheap generics and need to show significant additional benefits.

Reasons to Purchase

*Validate the market potential of particular ophthalmology indications based on prevalence numbers in each of the seven major markets

*Understand the commercial potential of ophthalmic diseases with Datamonitor’s assessment of market and brand dynamics

*Assess the key unmet needs and possible new approaches in the treatment of eye diseases as noted by opinion leaders

Ophthalmology market attractiveness
ophthalmology market definition
Therapeutic sales for ophthalmology disorders exceeded $12 billion in 2008
High growth potential observed in diabetic retinopathy and age-related macular degeneration markets
Age-related macular degeneration shows a high growth rate, and seemingly unsaturated market
Middle Eastern, North African (MENA) and Brazil, Russia, India and China (BRIC) ophthalmology markets are growing rapidly
High pipeline potential in age-related macular degeneration (AMD)
to greater patient compliance
Preservative-free formulations
Therapies with better side-effect profiles
Pipeline analysis of glaucoma treatments
Chapter 3. Age-related macular degeneration
Key findings 70
Definition and classification of age-related macular degeneration (AMD)
Dry (nonexudative) age-related macular degeneration
Wet (exudative/neovascular) age-related macular degeneration
Epidemiology of age-related macular degeneration (AMD)
Over 7.5 million sufferers of age-related macular degeneration in the seven major markets in 2010
estimates over 2.7 million cases of age-related macular degeneration in the US in 2010
Japanese males have higher prevalence of age-related macular degeneration
estimates over 4.3 million cases of age-related macular degeneration across the five major EU markets in 2010
Age-related macular degeneration prevalence is high in India
Age-related macular degeneration prevalence varies in racial groups
Current treatment options in age-related macular degeneration (AMD)
Overview of treatments in age-related macular degeneration (AMD)
Anti-vascular endothelial growth factor (VEGF) therapy
Off-label use of Avastin in age-related macular degeneration
Laser photocoagulation and photodynamic therapy
Other surgical treatments for AMD
Vitamins and lifestyle change are the main treatment options in dry AMD
Age-related macular degeneration (AMD) treatment guidelines Diagnosis of AMD
Treatment guidelines on the management of AMD
Sales analysis of brands in age-related macular degeneration (AMD)
Lucentis drives rapid growth in AMD market between 2004 and 2008
Major brands in AMD therapy
Lucentis (ranibizumab, Roche/Novartis/Alcon)
Macugen (pegaptanib, Eyetech/Pfizer)
Visudyne (verteporfin, QLT /Novartis)
Avastin (bevacizumab, Roche)